Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Most pharmaceuticals sold today have their origin in a biochemistry laboratory. Drug discovery has traditionally started with a biochemical pathway implicated in a pathophysiological process. An ...

Long before a liver tumor appears, a high-fat diet can push liver cells into a risky survival mode. That is the central ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Nandita Vijayasimha, Bengaluru Friday, January 2, 2026, 08:00 Hrs [IST] ...

Advancements in next-generation sequencing technologies, increasing adoption of precision oncology, and rising cancer incidence worldwide are driving the genomics in cancer care market growth.Austin, ...

Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite ...

An inherent principle of publication is that others should be able to replicate and build upon the authors' published claims. A condition of publication in a Nature Portfolio journal is that authors ...